| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
phosphate buffer: 1mg/mL, clear to slightly hazy (0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4, at 25 °C) | [form ]
Solid | [color ]
Off-white to pink | [biological source]
human milk | [Water Solubility ]
H2O: soluble 5mg/mL |
| Hazard Information | Back Directory | [Uses]
Lactoferrin was used to grow Streptococcus mutans in an iron-limiting medium. It was used to test if lactoferrin impedes epithelial cell adhesion in vitro. It was also used to test the diagnostic value of blood cytokine concentrations in acute pneumonia. | [Biological Activity]
Lactoferrin is blood-brain barrier (BBB) traversable and has therapeutic potential to regulate inflammationimmunity and apoptosis in Parkinsonμs disease. It promotes the expression of brain-derived neurotrophic factor (BDNF) via various signaling pathways and aids protection in motor dysfunction. Lactoferrin favors osteogenic differentiation and proliferation of human adipose-derived stem cells (hADSCs). It exhibits proteolytic activity on Haemophilus influenzae colonization factors. Lactoferrin is also a nutraceutical and a potential marker in the pathophysiology of inflammatory bowel diseasesleukocytes''Lactoferrin is an iron binding protein. It is structurally similar to transferrinthe plasma iron transport protein; but lactoferrin has a much higher affinity for iron (250 fold). | [in vivo]
Lactoferrin (recombinant human lactoferrin) (1,000 mg/kg, oral gavage, twice daily for 8 days) inhibits the growth of squamous cell carcinoma (O12) tumors in T cell–immunocompromised nu/nu mice by 80%[5].
Lactoferrin (Bovine lactoferrin) (100 and 200 mg/kg, oral gavage,for 30 consecutive days) shows protective effects in a rat model of sepsis-induced acute lung injury[6].
| Animal Model: | Squamous cell carcinoma model (O12 cell injected into the left flank of nu/numice)[5] | | Dosage: | 1,000 mg/kg | | Administration: | oral gavage, twice daily for 8 days | | Result: | Inhibited the tumor growth by 80%. |
| Animal Model: | Sepsis-induced acute lung injury rat model[6] | | Dosage: | 100 and 200 mg/kg | | Administration: | oral gavage,for 30 consecutive days | | Result: | Reduced the wet/dry ratio of lung tissue by 30.7% and 61.3%, and lipid peroxidation by 22.3% and 67%, at concentrations of 100 and 200mg/kg.
Reduced Inflammatory markers, neutrophils, lymphocytes and total cell count.
Reduced MPO activity.
|
|
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|